Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of Tinostamustine (EDO-S101) in Japanese Patients With Relapsed/Refractory Hematologic Malignancies
jRCT2080224049Phase 1Completed
- Sponsor
- Mundipharma
- Start
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tinostamustine in Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL) and multiple myeloma (MM), sponsored by Mundipharma. Started Sep 2018; status: completed.
02
Drugs
tinostamustine
03
Conditions
Hodgkin lymphoma (HL)non-Hodgkin lymphoma (NHL)multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2080224049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224049.